What does Westlaanapotheek do?

Westlaanapotheek is a pharmacy in Roeselare. Private Limited, started on 25 July 2003, 2 establishments.

What is the address of Westlaanapotheek?

The registered office of Westlaanapotheek is located at Westlaan 138, 8800 Roeselare.

Is Westlaanapotheek still active?

Yes. According to the CBE (29 October 2026) Westlaanapotheek is active, legal situation “Normale toestand”, started on 25 July 2003.

Is Westlaanapotheek registered on Peppol?

Yes, Westlaanapotheek is registered on the Peppol network with ID 0208:0859788697.

What is the enterprise number of Westlaanapotheek?

The enterprise number of Westlaanapotheek is BE0859788697.

When was Westlaanapotheek founded?

Westlaanapotheek was founded on 25 July 2003.

Who are the directors of Westlaanapotheek?

According to the 2025 annual accounts, the directors of Westlaanapotheek are: CORTEXCO BV.

Is Westlaanapotheek a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 25 July 2003; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account; 2 establishments in the CBE.

How much profit did Westlaanapotheek make in 2025?

Westlaanapotheek posted a profit after taxes of € 214,126 in financial year 2025.

What is the revenue of Westlaanapotheek?

As a small company, Westlaanapotheek is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 659,622.

How much does an employee at Westlaanapotheek earn?

The average wage cost per full-time employee at Westlaanapotheek was € 58,100 in 2025: staff costs of € 360,084 for 6.2 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Westlaanapotheek have?

According to the 2025 annual accounts, Westlaanapotheek has 6.2 full-time equivalents (FTE).

Westlaanapotheek (Private Limited) - Roeselare

Dossier Westlaanapotheek, printed on 29 October 2026 from databakkes.be/en/0859788697/westlaanapotheek. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Westlaanapotheek from Roeselare, company number BE0859788697, closed financial year 2025 with a result of € 214,126 after tax. For that financial year Westlaanapotheek recorded a gross margin of € 659,622 and equity of € 476,119. Compared with financial year 2024, the result moved from € 257,694 to € 214,126. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on April 30, 2026.

What it is worth Growing

€ 476,119

▲ 1% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 214,126

▼ 17% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 770,558

▼ 5% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 208,000 paid out

97 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents

6.2

▲ 0.6 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 360,084

▲ 12% vs 2024

€ 58,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 15,162

▼ 23% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 118,502

▼ 23% vs 2024

€ 38,976 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 725,609

▲ 30% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 29,706

▼ 9% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 570,278 Gross margin 2022: € 570,278 First fiscal year in the series	€ 627,602 Gross margin 2023: € 627,602 ▲ 10% vs 2022 (€ 570,278) Favourable step	€ 664,817 Gross margin 2024: € 664,817 ▲ 6% vs 2023 (€ 627,602) Favourable step	€ 659,622 Gross margin 2025: € 659,622 ▼ 1% vs 2024 (€ 664,817) Unfavourable step	▼ 1%
Profit after taxes	€ 181,417 Profit after taxes 2022: € 181,417 First fiscal year in the series	€ 190,385 Profit after taxes 2023: € 190,385 ▲ 5% vs 2022 (€ 181,417) Favourable step	€ 257,694 Profit after taxes 2024: € 257,694 ▲ 35% vs 2023 (€ 190,385) Favourable step	€ 214,126 Profit after taxes 2025: € 214,126 ▼ 17% vs 2024 (€ 257,694) Unfavourable step	▼ 17%
Equity	€ 459,913 Equity 2022: € 459,913 First fiscal year in the series	€ 469,798 Equity 2023: € 469,798 ▲ 2% vs 2022 (€ 459,913) Favourable step	€ 469,993 Equity 2024: € 469,993 Unchanged (€ 469,798) Favourable step	€ 476,119 Equity 2025: € 476,119 ▲ 1% vs 2024 (€ 469,993) Favourable step	▲ 1%
Total debts	€ 1,315,060 Total debts 2022: € 1,315,060 First fiscal year in the series	€ 1,348,885 Total debts 2023: € 1,348,885 ▲ 3% vs 2022 (€ 1,315,060) Unfavourable step	€ 1,481,992 Total debts 2024: € 1,481,992 ▲ 10% vs 2023 (€ 1,348,885) Unfavourable step	€ 1,561,244 Total debts 2025: € 1,561,244 ▲ 5% vs 2024 (€ 1,481,992) Unfavourable step	▲ 5%
Cash	€ 622,662 Cash 2022: € 622,662 First fiscal year in the series	€ 569,723 Cash 2023: € 569,723 ▼ 9% vs 2022 (€ 622,662) Unfavourable step	€ 815,161 Cash 2024: € 815,161 ▲ 43% vs 2023 (€ 569,723) Favourable step	€ 770,558 Cash 2025: € 770,558 ▼ 5% vs 2024 (€ 815,161) Unfavourable step	▼ 5%
Retained profit	€ 441,313 Retained profit 2022: € 441,313 First fiscal year in the series	€ 451,198 Retained profit 2023: € 451,198 ▲ 2% vs 2022 (€ 441,313) Favourable step	€ 451,393 Retained profit 2024: € 451,393 Unchanged (€ 451,198) Favourable step	€ 457,519 Retained profit 2025: € 457,519 ▲ 1% vs 2024 (€ 451,393) Favourable step	▲ 1%
Dividend	€ 180,000 Dividend 2022: € 180,000 First fiscal year in the series	€ 180,500 Dividend 2023: € 180,500 Unchanged (€ 180,000) Unchanged	€ 257,500 Dividend 2024: € 257,500 ▲ 43% vs 2023 (€ 180,500) Unchanged	€ 208,000 Dividend 2025: € 208,000 ▼ 19% vs 2024 (€ 257,500) Unchanged	▼ 19%
Bank debt	€ 498,475 Bank debt 2022: € 498,475 First fiscal year in the series	€ 220,358 Bank debt 2023: € 220,358 ▼ 56% vs 2022 (€ 498,475) Favourable step	€ 154,022 Bank debt 2024: € 154,022 ▼ 30% vs 2023 (€ 220,358) Favourable step	€ 118,502 Bank debt 2025: € 118,502 ▼ 23% vs 2024 (€ 154,022) Favourable step	▼ 23%
Balance sheet total	€ 1,774,973 Balance sheet total 2022: € 1,774,973 First fiscal year in the series	€ 1,818,683 Balance sheet total 2023: € 1,818,683 ▲ 2% vs 2022 (€ 1,774,973) Unchanged	€ 1,951,985 Balance sheet total 2024: € 1,951,985 ▲ 7% vs 2023 (€ 1,818,683) Unchanged	€ 2,037,363 Balance sheet total 2025: € 2,037,363 ▲ 4% vs 2024 (€ 1,951,985) Unchanged	▲ 4%
Employees (FTE)	5.9 Employees (FTE) 2022: 5.9 First fiscal year in the series	5.3 Employees (FTE) 2023: 5.3 ▼ 0.6 vs 2022 (5.9) Unchanged	5.6 Employees (FTE) 2024: 5.6 ▲ 0.3 vs 2023 (5.3) Unchanged	6.2 Employees (FTE) 2025: 6.2 ▲ 0.6 vs 2024 (5.6) Unchanged	▲ 0.6

Key figures of Westlaanapotheek, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.

What happened to Westlaanapotheek?

What happened at Westlaanapotheek in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Apr 30, 2026 New annual accounts for financial year 2025: profit of € 214,126 (▼ 17% vs 2024). Source: NBB ↗
Jan 25, 2019 New establishment in Roeselare. KBO
2009 CORTEXCO BV became a director. NBB
Oct 1, 2003 New establishment in Roeselare. KBO
Jul 25, 2003 Start of the company according to the CBE. KBO

In short

From € 181,417 profit in 2022 to € 214,126 profit in 2025.

Paid € 6,308 in corporate taxes since 2022.

Best year ever: 2024, with € 257,694 profit.

On average € 106,400 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

CORTEXCO BV

Westlaanapotheek

Apotheek Vichte

Apotheek De Klokkeput

PHARMA DMS

Behind Westlaanapotheek is CORTEXCO BV. CORTEXCO BV is also behind Apotheek Vichte, Apotheek De Klokkeput, PHARMA DMS, RCC PLAST and DERTIEN-ACHT.

Directors

According to the 2025 annual accounts

CORTEXCO BV

Director · represented by Tack Eveline

Also active at: Apotheek Vichte, Apotheek De Klokkeput, PHARMA DMS, RCC PLAST, DERTIEN-ACHT

since 2009

Establishments

Establishment units

Physical locations of this company

Registered office

Westlaan 138

8800 Roeselare

2.334.403.681

Diksmuidsesteenweg 346

8800 Roeselare

Active since 25 January 2019

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.

All companies at this address →

PHARMA DMS same network

€ 71,811 gross margin · 2025

DERTIEN-ACHT same network

€ 42,246 gross margin · 2025

CORTEXCO same network

€ 801,435 gross margin · 2025

GROEP WESTLAAN BTW EENHEID

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0859.788.697

VAT number

BE 0859.788.697

Registered office

Westlaan 138, 8800 Roeselare

Names & denominations

Westlaanapotheek

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

25 July 2003

Peppol

Active · Active since 3 Apr 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

Westlaanapotheek

Financials

What happened to Westlaanapotheek?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions